Hemogenyx Pharmaceuticals Share Discussion Threads

[tsmith2] 09/9/2024 06:57

more v decent news

[apotheki] 09/9/2024 06:55

FLT3 Assay Ready for Phase I Trials at MD Anderson


Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, is pleased to announce the successful completion of the development of a clinical-grade assay ("Assay") designed to assess FLT3 protein expression in acute myeloid leukemia ("AML") cells.

Assessing FLT3 protein expression in AML cells is crucial for the accurate identification and recruitment of patients for the imminent Phase I clinical trials of the Company's HEMO-CAR-T product candidate. The trials are expected to commence shortly at MD Anderson Cancer Center ("MD Anderson"), one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. The Phase I clinical trials are planned to expand to the University of Pennsylvania Medical Center thereafter.

Dr Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals, commented:
"The completion of our FLT3 assay marks a critical milestone in advancing our HEMO-CAR-T product candidate into clinical trials. This Assay will ensure we can accurately identify and recruit the right patients for the trials, bringing us one step closer to providing a potentially life-saving treatment for those battling AML. We are excited to begin our Phase I trials imminently at MD Anderson Cancer Center, a leading institution in cancer care, and look forward to expanding our efforts to the University of Pennsylvania Medical Center."

[tsmith2] 02/9/2024 08:21

promising news

[ashleyjv] 02/9/2024 08:10

2 September 2024



Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

CDX Development Update



Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, is pleased to announce that it has developed a new and improved version of its bi-specific antibody ("CDX") for the treatment of relapsed/refractory acute myeloid leukaemia ("AML"), a subset of acute lymphoblastic leukaemia ("ALL"), and potentially for conditioning in bone marrow transplantations.



The Company's scientists utilised Lonza's bYlok bispecific pairing technology to develop a new and improved version of CDX, which has demonstrated significantly enhanced efficacy in in vitro testing. Additional in vivo studies are currently underway.



Dr. Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals, commented:

"The development of an improved version of our CDX bi-specific antibody holds significant promise for enhancing treatment outcomes for patients battling often incurable blood cancers. This advancement could accelerate the progress of this product candidate and allow us to resume its development toward the clinic. It may also attract new industry partners interested in fast-tracking the co-development of CDX."

[denholm elliott] 29/8/2024 07:46

Another disaster for the 'AI' reports!What a tool

[socionomics] 19/8/2024 14:14

I have screenshotted, and will ask the company for comment.

[trader4ever] 29/7/2024 12:40

This company is run by Fraudster. JA has been deceiving shareholders for many years. (IMO - at least for last 5 years he pumped share prices by giving false info/hope before placing to raise more funds to pay himself and his corrupt team huge salaries)

[apotheki] 29/7/2024 06:50

Presentation at Macrophage-Directed Therapies Summit

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 6th Macrophage-Directed Therapies Summit ("Summit"), which will be held on October 1-3, 2024, in Boston, MA. The Company will present its work on its proprietary Chimeric Bait Receptor ("CBR") platform.

The Company's CBR platform is an advanced immunotherapy designed to program or redirect innate immune cells, such as macrophages, to eliminate specific types of cancer as well as combat infections from both existing and emerging viral threats. The Company's presentation at the Summit will focus on the use of the CBR platform for the treatment of rare cancers.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the Summit will provide the Company with an opportunity to further establish its unique position in the emerging field of myeloid cell therapies. It will also allow us to exchange ideas with like-minded cell therapy developers, potential collaborators, and investors."

[gah123] 26/7/2024 08:43

Next 5 bagger - adding as funds clear

[purple11] 26/7/2024 08:01

im back in gla

[orchestralis] 26/7/2024 07:55

Tide is turning perhaps

[gah123] 19/7/2024 08:09

Pharma season is here, hemo next to go. Offloading a few others soon.

[marcus80] 16/7/2024 08:08

another Pharma delisting DEST! tick tock. very risky now here

[countbasie1] 10/7/2024 07:11

Did Apotheki recommend buying this at 1.95 to a distressed poster?Shameful. Low life.

[marcus80] 17/6/2024 15:25

Would surprise me If this hold 1p this time.

[marcus80] 17/6/2024 15:24

Will need funding before end of summer. Will drop slowly below 1p this time And doubt vlad even can raise funds that low. Delisting possible here

[gah123] 17/6/2024 10:48

Back in very good value down here. Holding for 5p+ as long as it takes.

[trying2trade] 17/6/2024 08:29

An RNS with almost nothing to add value there. And of course Vlad and his record of any type of news is to pump the share price before a raise.

[apotheki] 17/6/2024 06:55

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its ongoing activities and progress.

1. HEMO-CAR-T

Clinical Trials Progress:

· Additional Clinical Trial Site: The Company has added an additional prestigious US medical center to its list of clinical trial sites. This will enhance the scope and expedite the timeline for the implementation of clinical trials.

· Clinical Site Setup: The setup of clinical sites at the University of Pennsylvania ("PENN") and the new medical centre is underway. This multi-step process involves thorough internal reviews by the science review committee and the internal review board of both clinical sites, as well as budget negotiations and logistics planning. The Company continues to work with Prevail Infoworks, a contract research organization ("CRO"), to manage and oversee the planning for the clinical trials.

Expansion into Pediatric Indications:

Pediatric AML and ALL: The Company is seeking to expand the HEMO-CAR-T indication to include pediatric acute myeloid leukemia ("AML") and a subset of pediatric acute lymphoblastic leukemia ("ALL") patients. An amendment to the clinical protocol to include pediatric AML is currently under review by third party experts. If approved, the Company will seek to implement the clinical trials for pediatric AML at the newly established clinical site. This area is of particular concern, and there is an urgent need for effective treatments for these conditions, which the Company believes HEMO-CAR-T will be able to provide.

2. Chimeric Bait Receptor ("CBR") Platform

The Company's CBR platform is an advanced immunotherapy designed to reprogram or redirect innate immune cells, such as macrophages, to prevent and combat infections from both existing and emerging viral threats, as well as to eliminate specific types of cancer.

Development and Testing:

· CBR Constructs: Scientists at Hemogenyx Pharmaceuticals are developing and testing multiple CBR constructs to identify the best candidates for targeting rare cancers such as epithelial ovarian carcinoma. Selected candidates will undergo rigorous testing to advance them to investigational new drug (IND) enabling studies.

mRNA-Based Delivery of CBR:

· Intranasal Delivery for Viral Infections: The Company continues to develop mRNA-based delivery of CBRs for treating airborne viral infections via intranasal administration. Recent improvements in the stability of mRNA-based CBRs are expected to enhance the effectiveness of this treatment.

3. CDX - Bispecific Antibody

IND-Enabling Studies:

· Progress: The Company is advancing IND-enabling studies for CDX, a bispecific antibody designed for treating relapsed and/or refractory AML, a subset of ALL, and for conditioning in bone marrow transplants.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are excited about the progress we are making across our various programs. The addition of a world-renowned medical center to our HEMO-CAR-T clinical trial sites marks a significant step forward in our mission to develop life-saving therapies. Our expansion into pediatric indications for HEMO-CAR-T highlights our commitment to addressing unmet medical needs in both adult and pediatric populations.

"Furthermore, our advancements in the CBR platform and the development of mRNA-based delivery systems for treating airborne viral infections demonstrate our innovative approach to tackling complex diseases. The progress in our CDX bispecific antibody program also underscores our dedication to bringing effective treatments to patients with relapsed or refractory AML and other severe conditions.

"We are diligently pursuing non-dilutive financing options to support these initiatives and remain focused on translating our scientific discoveries into clinical success. We look forward to updating our shareholders and the market as we continue to make strides in our development programs."

[countbasie1] 04/6/2024 18:39

Spotheki was buying this at 2. But shockingly was giving financial advice to a distressed investor to buy at 1.95.What a low life thing to do.

[dreamtwister] 16/5/2024 20:21

a positive proof of concept....reassuring to watch..

[bahamarama] 12/5/2024 20:34

Correct, Marcus.I will be one of many who have learned the hard way that money is not MADE easily in these markets. But it is certainly TAKEN easily.And the wise among us will NOT continuously blame performance and delivery failures.They want OUR money FAR more than we might hope for THEIRS.

[marcus80] 09/5/2024 13:08

penny stock will delist next year